Non-Prostanoid EP4 Agonist Compounds For Inflammatory Bowel Disease Treatment

Lead compound 11a demonstrated efficacy in a mouse model of inflammatory bowel disease and induced known hemodynamic changes in systemic circulation. Heidi L. Perez published this dataset on figshare in April 2026, detailing structure-activity relationship studies from a high-throughput screening campaign. The dataset contains chemical and biological data supporting the discovery of a novel agonist chemotype.

Use Cases

• Analyze structure-activity relationship trends across the agonist series to identify key molecular features for EP4 binding.
• Correlate pharmacokinetic parameters from mouse studies with in vivo efficacy metrics in the IBD model.
• Validate computational binding models using high-throughput mutagenesis data for the EP4 receptor orthosteric site.
• Compare the hemodynamic effect profile of lead compound 11a against known prostanoid EP4 agonists.

Strengths

• Data originates from a published high-throughput screening campaign and follow-up optimization studies.
• Includes in vivo proof-of-concept from a mouse pharmacokinetic study and disease model.

Limitations

• The dataset is very small at 33.5 KB, indicating limited chemical or biological data points.
• Data is restricted to a single lead series and one specific mouse model, limiting generalizability.
• License is CC-BY-NC-4.0, prohibiting commercial use without permission.

Provenance

Source

Heidi L. Perez via figshare.

Collection Method

High-throughput screening followed by structure-activity relationship studies and in vivo profiling.

Time Range

null

Freshness

Last updated in April 2026.

Geography

null